Photo: Andy Ryan
Photo: Andy Ryan

Since its inception in 2011, the Bridge Project—a research collaboration between the Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center (DFHCC)—has supported 15 cross-institutional teams that are working to make advances in cancer therapeutics and diagnostics. Now, thanks to a $20 million gift from the Commonwealth Foundation for Cancer Research, the Bridge Project is poised to accelerate its fight against cancer.

The Commonwealth Foundation gift will be distributed over the next five years, doubling the number of grants available to fund research teams. And there is no shortage of worthy projects to fund: As Tyler Jacks, director of the Koch Institute, recently told MIT Spectrum, “It’s time to expand. Every year we leave on the table highly ranked and meritorious grants that we wish we could fund.”

Bridge-funded research is focused on making advances in the treatment of cancer types that represent areas of greatest clinical need, including brain, breast, lung, ovarian, and advanced prostate.

“We are so proud to continue our support of the Bridge Project. Over the last four years, we have witnessed some truly innovative advances,” Bill Goodwin, chair of the Commonwealth Foundation for Cancer Research, said in a press release. “We share the Bridge Project’s goal to move important discoveries out of the lab and into the clinic—and hope other families and foundations will be inspired to join this effort.” The Commonwealth Foundation began working with the Bridge Project in 2012.


Read more about the Commonwealth Foundation’s commitment to the Bridge Project at MIT News.

Learn about how the Bridge Project is advancing cancer solution in the Fall 2015 issue of Spectrum.

Detailed information about Bridge-funded research is available at The Bridge Project website.

Related Topics

Share your thoughts

Thank you for your comments and for your role in creating a safe and dynamic online environment. MIT Spectrum reserves the right to remove any content that is deemed, in our sole view, commercial, harmful, or otherwise inappropriate.

Your email address will not be published. Required fields are marked *